Insmed: FDA won’t hold advisory meeting to discuss NDA for brensocatib

Insmed (INSM) announced that the U.S. Food and Drug Administration FDA has informed the company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application for brensocatib for patients with non-cystic fibrosis bronchiectasis. The FDA provided this update in its Day 74 communication to Insmed. “We are very pleased with our ongoing communications with the FDA about the NDA for brensocatib,” said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. “We are committed to working closely with the agency to successfully complete the review and potentially bring forward this much-needed treatment for patients with bronchiectasis.”